

PRODUCT DATASHEET
ChemiScreen™ CXCR3 Membrane Preparation

CATALOG NUMBER: HTS003M **QUANTITY:** 200 units
LOT NUMBER: **VOLUME/CONCENTRATION:** 1 mL, 1 mg/mL

BACKGROUND: CXCR3 is a 7-TM GPCR that is selective for the CXC chemokines IP10, ITAC and MIG (Loetscher *et al.*, 1996). Binding of IP10 and MIG to CXCR3 induces Ca²⁺ mobilization, chemotaxis and inflammatory responses of T lymphocytes, and also act as potent inhibitors of angiogenesis. CXCR3 is highly expressed in IL-2-activated T lymphocytes in vitro (Loetscher *et al.*, 1996) and in T lymphocytes present in inflamed tissues in rheumatoid arthritis and multiple sclerosis (Balashoy *et al.*, 1999; Qin *et al.*, 1998). In vivo, neutralization of CXCR3 inhibits experimentally induced type I diabetes (Frigerio *et al.*, 2002), peritonitis (Xie *et al.*, 2003), and post-lung transplantation bronchiolitis obliterans syndrome (Belperio *et al.*, 2002). ChemiScreen™ CXCR3 membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression. Thus, they are ideal HTS tools for screening of agonists of CXCR3 receptor interactions. The membrane preparations exhibit a K_d of 2.6 nM for [¹²⁵I]-IP-10. With 5 µg/well of CXCR3 Membrane Prep and 0.1 nM [¹²⁵I]-IP-10, a greater than 10-fold signal-to-background ratio was obtained.

APPLICATIONS: Radioligand Binding Assay




Figure 1. Saturation Binding for CXCR3. 5 µg/well of CXCR3 Membrane Preparation were incubated with increasing amounts [¹²⁵I]-IP-10 in the absence (TB: total binding) or presence (NSB: nonspecific binding) of a 200-fold excess of unlabeled IP-10. Specific binding (SB) was determined by subtracting NSB from TB. The data are from a representative sample of lot SC.




Figure 2. Competition Binding for CXCR3. 5 µg/well of CXCR3 Membrane Preparation or Wild-Type Chem-1 Membrane Preparation (Catalog # HTS000MC1) were incubated with 0.1 nM [¹²⁵I]-IP-10 and increasing concentrations of unlabeled IP-10, and more than a 10-fold signal:background ratio was obtained. The data are from a representative sample of lot SC.

SPECIFICATIONS: 1 unit = 5 µg membrane preparation
 B_{max} for [¹²⁵I]-IP-10 Binding: 0.6 pmol/mg protein
 K_d for [¹²⁵I]-IP-10 Binding: ~0.2 nM
 Signal:Background: ≥10-fold

TRANSFECTION: Full-length human CXCR3 cDNA (Accession Number: X95876).

HOST CELLS: Chem-1, an adherent mammalian cell line without any endogenous CXCR3 receptor expression

RECOMMENDED ASSAY CONDITIONS: Membranes were mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a non-binding 96-well plate and incubated for 2 h at room temperature. Prior to filtration, an FC 96-well harvest plate was coated with 0.33% polyethyleneimine for 30 min, then washed with 50 mM HEPES, pH 7.4, 0.5% BSA. The binding reactions were transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The wells were then dried and counted for determination of receptor-associated radioligand binding.

Binding Buffer: 50 mM HEPES, pH 7.4, 5 mM MgCl₂, 1 mM CaCl₂, 0.2% BSA, filtered and stored at 4°C

Radioligand: [¹²⁵I]-IP-10 (PerkinElmer # NEX348)

Wash Buffer: 50 mM HEPES, pH 7.4, 500 mM NaCl, 0.1% BSA, filtered and stored at 4°C

One package contains enough membranes for at least 200 assays (units), where a unit is the amount of membrane that will yield greater than a 10-fold signal:background ratio with [¹²⁵I]-IP-10 at 0.1 nM.

PRESENTATION:

Liquid in packaging buffer: 50 mM Tris, pH 7.4, 10% glycerol, and 1% BSA with no preservatives.

Packaging method: Membrane proteins were adjusted to 1 mg/mL in packaging buffer, dispensed at 1 mL per vial, rapidly frozen, and stored at -80°C.

STORAGE/HANDLING: Store at -70°C . Product is stable for at least 6 months from the date of receipt when stored as directed. Avoid repeated freeze/thaw cycles.

- REFERENCES:**
1. Balashov KE, *et al.* (1999) CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1 α and IP-10 are expressed in demyelinating brain lesions. *Proc. Natl. Acad. Sci. USA* 96:6873-8.
 2. Belperio JA, *et al.* (2002) Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. *J. Immunol.* 169:1037-1049.
 3. Frigerio S, *et al.* (2002) Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulinitis. *Nat. Med.* 8:1414-20.
 4. Loetscher M, *et al.* (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. *J Exp Med.* Sep 1; 184(3):963-9.
 5. Qin S, *et al.* (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J. Clin. Invest.* 101:746-54.
 6. Xie JH, *et al.* (2003) Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. *J. Leukoc. Biol.* 73:771-7-80.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES.
NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

No part of these works may be reproduced in any form without permission in writing.

Eurofins Pharma Bioanalytics Services US Inc. is an independent member of Eurofins Discovery Services.